Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium lactis is a probiotic that has been investigated for its potential benefits in supporting individuals with Celiac Disease (CeD), an autoimmune disorder triggered by gluten ingestion. The rationale for its use stems from the recognition that people with CeD often exhibit altered gut microbiota, including reduced levels of beneficial Bifidobacteria. Some small-scale clinical studies and in vitro experiments suggest that B. lactis may help modulate the gut microbiota, reduce intestinal inflammation, and enhance the intestinal barrier, which are relevant factors in CeD pathology. For example, a randomized controlled trial in children with newly diagnosed CeD showed that supplementation with B. lactis (in combination with other probiotics) improved gut microbiota composition and reduced markers of inflammation. Laboratory studies have also indicated that B. lactis can decrease the toxicity of gliadin (the problematic gluten component) and modulate immune responses. However, these findings are preliminary and the overall quality and quantity of evidence are limited. Larger, long-term clinical trials are lacking, and most studies use B. lactis as part of a probiotic mixture rather than in isolation. Current guidelines do not recommend probiotics, including B. lactis, as a standard therapy for CeD. Thus, while there is a scientific rationale and some early evidence for the use of B. lactis in CeD, the support is modest and more research is needed to determine its clinical efficacy.

More about bifidobacterium lactis
More about Celiac Disease

Other ingredients used for Celiac Disease

Other health conditions supported by bifidobacterium lactis

Products containing bifidobacterium lactis